Abstract
Zaleplon is a pyrrazolopyrimidine which is recommended for the treatment of insomnia and pentylenetetrazole/ electroshock-induced convulsions is an effective anticonvulsant which potential acts on the GABA receptor. The poor oral bioavailability of zaleplon (~30%) is due to the low solubility which in turn amputates the dissolution of the drug, restricts gastric absorption and first-pass metabolism. It is now withdrawn from the market due to the high dose and inefficient therapeutic activity. This review focuses on the various drug systems of zaleplon such as solid dispersions, self-nanoemulsifying, solid dispersions, proliposomes and solid lipid nanoparticles to enhance the oral bioavailability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
